In multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely detected at diagnosis. Using small-molecule inhibitors of MDM2, we provide evidence that miR-192, 194, and 215, which are downregulated in a subset of newly diagnosed MMs, can be transcriptionally activated by p53 and then modulate MDM2 expression. Furthermore, ectopic re-expression of these miRNAs in MM cells increases the therapeutic action of MDM2 inhibitors in vitro and in vivo by enhancing their p53-activating effects. In addition, miR-192 and 215 target the IGF pathway, preventing enhanced migration of plasma cells into bone marrow. The results suggest that these miRNAs are positive regulators of p53 and that their downregulation plays a key ...
Progress in understanding the biology of multiple myeloma (MM), a plasma cell malignancy, has been s...
A rising body of evidence suggests that silencing microRNAs (miRNAs) with oncogenic potential may re...
Progress in understanding the biology of multiple myeloma (MM), a plasma cell malignancy, has been s...
SummaryIn multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely...
In multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely detect...
In multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely detect...
SummaryIn multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely...
The analysis of deregulated microRNAs (miRNAs) is emerging as a novel approach to disclose the regul...
The analysis of deregulated microRNAs (miRNAs) is emerging as a novel approach to disclose the regul...
The analysis of deregulated microRNAs (miRNAs) is emerging as a novel approach to disclose the regul...
The analysis of deregulated microRNAs (miRNAs) is emerging as a novel approach to disclose the regul...
The analysis of deregulated microRNAs (miRNAs) is emerging as a novel approach to disclose the regul...
Abstract The molecular mechanisms underlying dysregulated wild type (wt) p53 in multip...
Abstract The molecular mechanisms underlying dysregulated wild type (wt) p53 in multip...
Abstract The molecular mechanisms underlying dysregulated wild type (wt) p53 in multiple myeloma (MM...
Progress in understanding the biology of multiple myeloma (MM), a plasma cell malignancy, has been s...
A rising body of evidence suggests that silencing microRNAs (miRNAs) with oncogenic potential may re...
Progress in understanding the biology of multiple myeloma (MM), a plasma cell malignancy, has been s...
SummaryIn multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely...
In multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely detect...
In multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely detect...
SummaryIn multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely...
The analysis of deregulated microRNAs (miRNAs) is emerging as a novel approach to disclose the regul...
The analysis of deregulated microRNAs (miRNAs) is emerging as a novel approach to disclose the regul...
The analysis of deregulated microRNAs (miRNAs) is emerging as a novel approach to disclose the regul...
The analysis of deregulated microRNAs (miRNAs) is emerging as a novel approach to disclose the regul...
The analysis of deregulated microRNAs (miRNAs) is emerging as a novel approach to disclose the regul...
Abstract The molecular mechanisms underlying dysregulated wild type (wt) p53 in multip...
Abstract The molecular mechanisms underlying dysregulated wild type (wt) p53 in multip...
Abstract The molecular mechanisms underlying dysregulated wild type (wt) p53 in multiple myeloma (MM...
Progress in understanding the biology of multiple myeloma (MM), a plasma cell malignancy, has been s...
A rising body of evidence suggests that silencing microRNAs (miRNAs) with oncogenic potential may re...
Progress in understanding the biology of multiple myeloma (MM), a plasma cell malignancy, has been s...